Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 8:13:33.
doi: 10.1186/1471-2377-13-33.

Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study

Affiliations

Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study

Nasrin Asgari et al. BMC Neurol. .

Abstract

Background: Neuromyelitis optica (NMO) includes transverse myelitis, optic neuritis and brain lesions. Recent studies have indicated that the brainstem is an important site of attack in NMO. Longitudinally extensive transverse myelitis (LETM) is an important component of the clinical diagnosis of NMO. The frequency of brainstem and LETM lesions, changes over time of LETM and the clinical consequences in the course of NMO have only been sparsely studied.

Methods: The study was a population-based retrospective case series with clinical and magnetic resonance imaging (MRI) follow-up of 35 patients with definite NMO and a relapsing-remitting course.

Results: Brainstem lesions were observed in 25 patients, 18 in medulla oblongata (11 in area postrema). Lesions in the pons, mesencephalon and diencephalon occurred in 10, 7 and 7 patients, respectively. Lesions were symptomatic in medulla oblongata and pons, asymptomatic in mesencephalon and diencephalon. Brainstem lesions were observed significantly more often in anti-aquaporin-4 (AQP-4) antibody positive than in seronegative patients (p < 0.002).LETM was demonstrated by MRI of the spinal cord in 30/36 patients, 23/30 of whom had follow-up MRI of the spinal cord. Recurrent LETM was observed in five patients. In nine patients the LETM changed into multiple lesions during remission or treatment. Spinal cord atrophy was observed in 12/23 (52%) patients, correlating to Expanded Disability Status Scale (r = 0.88, p < 0.001).

Conclusions: NMO patients had frequent occurrence of brainstem lesions and LETM. Brainstem lesions were associated with anti-AQP4 antibody positivity. LETM lesions differentiated over time and the outcome included relapses, fragmentation and atrophy. Correlation was observed between spinal cord atrophy and neurological disability.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Typical brain MRI lesions in neuromyelitis optica. Representative MRI of six NMO patients; Upper row: FLAIR; lower row: T2W, A. Lesions in hypothalamic region, B. Lesions in periaqueductal matter in mesencephalon, C and D. Lesions in medulla oblongata, E and F. Lesions in area postrema of the medulla oblongata.
Figure 2
Figure 2
Characteristics of follow-up MRI of longitudinally extensive transverse myelitis (LETM) in 23 NMO patients.
Figure 3
Figure 3
Modifications of longitudinally extensive transverse myelitis (LETM). Spinal cord MRI: sagittal T2WI of spinal cord from an anti-AQP4 antibody positive patient with NMO A: primary LETM in the upper thoracic cord (arrow) extending from Th1 – 6 (lower limit not shown) B: Fragmentation (small arrows) of the earlier LETM following treatment with high-dose steroids and a new LETM (circle) in the lower cervical cord 3 months later.
Figure 4
Figure 4
Longitudinally extensive transverse myelitis (LETM) and atrophy of spinal cord following LETM. Spinal cord MRI: sagittal T2WI (A and B) and T1WI (C) from three anti-AQP4- antibody positive NMO patients. A. MRI showing cervical spinal cord LETM with swelling. B. MRI showing LETM of cervical and upper 2/3 thoracic spinal cord. C. Severe atrophy of spinal cord as a consequence of recurrent LETM after 6 years duration of disease.

References

    1. Cloys D, Netsky M. In: Handbook of clinical neurology. 9. Viken PJ BG, editor. North-Holland: Amsterdam; 1970. Neuromyelitis optica; pp. 426–436.
    1. Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011;76:1589–1595. doi: 10.1212/WNL.0b013e3182190f74. - DOI - PMC - PubMed
    1. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63:390–396. doi: 10.1001/archneur.63.3.390. - DOI - PubMed
    1. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485–1489. doi: 10.1212/01.wnl.0000216139.44259.74. - DOI - PubMed
    1. Collongues N, Marignier R, Zephir H, Papeix C, Blanc F, Ritleng C. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology. 2010;74:736–742. doi: 10.1212/WNL.0b013e3181d31e35. - DOI - PubMed

Publication types

LinkOut - more resources